Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 4, 2002, Pages 403-410

  Jilma, Bernd ^a,b,c   Marsik, Claudia ^a,b,c   Mayr, Florian ^a,b,c   Graninger, Monika T ^a,b,c   Taylor Jr , Fletcher B ^a,b,c   Ribel, Mette C ^a,b,c   Erhardtsen, Elisabeth ^a,b,c   Handler, Sylvia ^a,b,c   Eichler, Hans Georg ^a,b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Oklahoma Medical Research Foundation   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; D DIMER; DROTRECOGIN; ELASTASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESCHERICHIA COLI ENDOTOXIN; FIBRIN; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; PENTASACCHARIDE; PLACEBO; PROTEIN C; PROTEIN S; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; ESCHERICHIA COLI; FIBRIN FORMATION; FIBRINOLYSIS; GRAM NEGATIVE SEPSIS; HUMAN; INFLAMMATION; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTIPLASMIN; BINDING SITES; BLOOD COAGULATION; DOUBLE-BLIND METHOD; E-SELECTIN; ENDOTOXINS; FACTOR VIIA; FEVER; HUMANS; INTERLEUKIN-6; MALE; P-SELECTIN; PANCREATIC ELASTASE; PLASMIN; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036794013     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127740     Document Type: Article

References (30)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-23.
2. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82:695-705.
3. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983;49:5-7.
4. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975;30:311-6.
5. Moldow CF, Bach RR, Staskus K, Rick PD. Induction of endothelial tissue factor by endotoxin and its precursors. Thromb Haemost 1993;70:702-6.
6. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995;73:223-30.
7. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124-9.
8. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-20.
9. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998;91:1609-15.
10. Hedner U, Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann Med 2000;32(Suppl 1):68-72.
11. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, Tropea M, Reda D, Agosti JM, et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998;80:114-8.
12. Hollenstein U, Homoncik M, Knöbl P, Pernerstorfer T, Graggaber J, Eichler HG, et al. Acenocoumarol decreases tissue factor dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002;71:368-74.
13. Poloyac SM, Tosheva RT, Gardner BM, Shedlofsky SI, Blouin RA. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clin Pharmacol Ther 1999;66:554-62.
14. Suffredini AF, Hochstein HD, McMahon FG. Doserelated inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278-82.
15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
16. Pernerstorfer T, Hollenstein U, Hansen JB, Stohlawetz P, Eichler HG, Handler S, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000;95:1729-34.
17. Pernerstorfer T, Stohlawetz P, Hollenstein U, Dzirlo L, Eichler HG, Kapiotis S, et al. Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol 1999;19:2517-23.
18. Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999;100:2485-90.
19. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997;77:1077-80.
20. Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997; 128:135-8.
21. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999;159:857-63.
22. Pernerstorfer T, Schmid R, Bieglmayer C, Eichler HG, Kapiotis S, Jilma B. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther 1999;66:51-7.
23. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986; 41:489-90.
24. Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001;41:880-5.
25. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89:3727-34.
26. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of anti-inflammatory and anti-adhesive effects of heparins in human endotoxemia. Crit Care Med. In press 2002.
27. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001;183:1815-8.
28. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000;95:1113-6.
29. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-6.
30. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.